Incyte to Report Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Mizuho Securities Reiterates Buy Rating on Incyte (INCY)
October 14, 2019 6:49 AM EDTMizuho Securities analyst Mara Goldstein reiterated a Buy rating and $95.00 price target on Incyte (NASDAQ: INCY) following the company's 52 weeks of study from the Phase II rux cream trial. The key takeaway, in our view, coming from the additional 28 weeks of... More
